Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis | MicrobiomeTrials← Back to trialsNCT07650942
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2028-05
Enrollment target: 360 participants Locations- The First Affiliated Hospital,Sun Yat-Sen University, Guangzhou, China
- The Sixth Affiliated Hospital,Sun Yat-Sen University, Guangzhou, China
Other microbiome trials you might be interested in
Ulcerative Colitis
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric …
Los Angeles, United StatesEst. completion Apr 14, 2027
Ulcerative Colitis (UC)
Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory…
Cairo, EgyptEst. completion Dec 15, 2028